Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States

Journal of Clinical Microbiology

Volumn 49, Issue 11, 2011, Pages 3849-3854

  Adams Haduch, Jennifer M ^a   Onuoha, Ezenwa O ^a   Bogdanovich, Tatiana ^a   Tian, Guo Bao ^a,b   Marschall, Jonas ^c   Urban, Carl M ^d   Spellberg, Brad J ^e   Rhee, Diane ^f   Halstead, Diane C ^g   Pasculle, Anthony W ^a   Doi, Yohei ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b SICHUAN UNIVERSITY   (China)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK HOSPITAL QUEENS   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^g BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLAOXA 23 GENE; CARBAPENEM NONSUSCEPTIBLE ACINETOBACTER BAUMANNII; CONTROLLED STUDY; HOSPITAL; ISABA1 BLAOXA 51 LIKE GENE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; UNITED STATES;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CLUSTER ANALYSIS; CROSS INFECTION; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; UNITED STATES;

ACINETOBACTER BAUMANNII;

EID: 80355145044     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00619-11     Document Type: Article

References (39)

1. Adams-Haduch, J. M., et al. 2008. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob. Agents Chemother. 52:3837-3843.
2. Bartual, S. G., et al. 2005. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J. Clin. Microbiol. 43:4382-4390. (Pubitemid 41298217)
3. Betrosian, A. P., et al. 2007. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand. J. Infect. Dis. 39:38-43. (Pubitemid 46277146)
4. Bratu, S., et al. 2008. Correlation of antimicrobial resistance with β-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob. Agents Chemother. 52:2999-3005.
5. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Diancourt, L., et al. 2010. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One 5:e10034.
7. Dijkshoorn, L., et al. 1996. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J. Clin. Microbiol. 34:1519-1525. (Pubitemid 26161019)
8. Doi, Y., et al. 2009. Extensively drug-resistant Acinetobacter baumannii. Emerg. Infect. Dis. 15:980-982.
9. Ecker, J. A., et al. 2006. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J. Clin. Microbiol. 44:2921-2932. (Pubitemid 44228591)
10. Feil, E. J., et al. 2004. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J. Bacteriol. 186:1518-1530. (Pubitemid 38248742)
11. Fu, Y., et al. 2010. Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. J. Antimicrob. Chemother. 65:644-650.
12. Grisold, A. J., et al. 2010. Use of automated repetitive-sequence-based PCR for rapid laboratory confirmation of nosocomial outbreaks. J. Infect. 60:44-51.
13. .Grosso, F., et al. 2011. OXA-23-producing Acinetobacter baumannii: a new hotspot of diversity in Rio de Janeiro? J. Antimicrob. Chemother. 66:62-65.
14. Hamouda, A., et al. 2010. Characterization of epidemiologically unrelated Acinetobacter baumannii isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of blaOXA-51-like genes. J. Clin. Microbiol. 48:2476-2483.
15. Higgins, P. G., et al. 2010. Global spread of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65:233-238.
16. Ho, P. L., et al. 2010. Epidemiology and clonality of multidrug-resistant Acinetobacter baumannii from a healthcare region in Hong Kong. J. Hosp. Infect. 74:358-364.
17. Kallen, A. J., et al. 2010. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect. Control Hosp. Epidemiol. 31:528-531.
18. Lee, Y., et al. 2010. Carbapenem-non-susceptible Acinetobacter baumannii of sequence type 92 or its single-locus variants with a G428T substitution in zone 2 of the rpoB gene. J. Antimicrob. Chemother. 66:66-72.
19. Marti, S., et al. 2008. Characterization of the carbapenem-hydrolyzing oxacillinase OXA-58 in an Acinetobacter genospecies 3 clinical isolate. Antimicrob. Agents Chemother. 52:2955-2958.
20. Martinovich, A., et al. 2009. Multilocus sequence typing of Acinetobacter strains from Russia and Belarus that produce acquired OXA carbapenemases, abstr. C2-626. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
21. Mera, R. M., et al. 2010. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb. Drug Resist. 16:209-215.
22. Mugnier, P. D., et al. 2010. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg. Infect. Dis. 16:35-40.
23. Oliveira, M. S., et al. 2008. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother. 61:1369-1375. (Pubitemid 351753609)
24. Park, Y. K., et al. 2010. A single clone of Acinetobacter baumannii, ST22, is responsible for high antimicrobial resistance rates of Acinetobacter spp. isolates that cause bacteremia and urinary tract infections in Korea. Microb. Drug Resist. 16:143-149.
25. Peleg, A. Y., et al. 2007. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother. 59:128-131. (Pubitemid 46017915)
26. Peleg, A. Y., et al. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
27. Perez, F., et al. 2010. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J. Antimicrob. Chemother. 65:1807-1818.
28. Reid, G. E., et al. 2007. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27:1198-1201. (Pubitemid 47173663)
29. Runnegar, N., et al. 2010. Molecular epidemiology of multi-resistant Acinetobacter baumannii in a single institution over a ten year period. J. Clin. Microbiol. 48:4051-4056.
30. Seifert, H., et al. 2005. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J. Clin. Microbiol. 43:4328-4335. (Pubitemid 41298209)
31. Shelburne, S. A., III, et al. 2008. Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J. Clin. Microbiol. 46:198-205.
32. Singh, A., et al. 2006. Application of molecular techniques to the study of hospital infection. Clin. Microbiol. Rev. 19:512-530. (Pubitemid 44134307)
33. Tian, G. B., et al. 2010. Identification of diverse OXA-40-group carbapenemases including a novel variant, OXA-160, from Acinetobacter baumannii in Pennsylvania. Antimicrob. Agents Chemother. 55:429-432.
34. Turton, J. F., et al. 2006. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 258:72-77.
35. Turton, J. F., et al. 2006. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J. Clin. Microbiol. 44:2974-2976. (Pubitemid 44228598)
36. Urban, C., et al. 1995. Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii. FEMS Microbiol. Lett. 125:193-198.
37. van Dessel, H., et al. 2004. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res. Microbiol. 155:105-112.
38. Wisplinghoff, H., et al. 2010. MLST-based molecular epidemiology of clinical Acinetobacter baumannii bloodstream isolates from 52 hospitals in the US, abstr. C2-590. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.
39. Woodford, N., et al. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27:351-353.